Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 21.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 656,250 shares of the company’s stock after purchasing an additional 117,536 shares during the period. Federated Hermes Inc. owned approximately 0.77% of Syndax Pharmaceuticals worth $13,473,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of SNDX. nVerses Capital LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $33,000. Quadrant Capital Group LLC raised its stake in shares of Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after acquiring an additional 1,496 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Syndax Pharmaceuticals by 28.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after acquiring an additional 1,587 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Syndax Pharmaceuticals by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares during the period. Finally, EntryPoint Capital LLC boosted its position in shares of Syndax Pharmaceuticals by 487.1% during the 1st quarter. EntryPoint Capital LLC now owns 8,636 shares of the company’s stock worth $206,000 after purchasing an additional 7,165 shares during the period.

Analyst Ratings Changes

A number of equities analysts recently weighed in on SNDX shares. Scotiabank cut shares of Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 14th. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Bank of America increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Barclays raised their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Finally, HC Wainwright raised their price target on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Syndax Pharmaceuticals Trading Down 4.8 %

Syndax Pharmaceuticals stock opened at $18.20 on Tuesday. The stock has a market cap of $1.55 billion, a P/E ratio of -5.65 and a beta of 0.91. The company has a fifty day simple moving average of $21.10 and a 200-day simple moving average of $21.29. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.22 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million for the quarter. The company’s revenue was up 3499999990.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.64) earnings per share. As a group, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).